Adicet Bio(ACET)
Focus: Adicet Bio is a publicly-traded immunotherapy company focused on oncology, leveraging cell engineering and targeted approaches to develop next-generation cancer treatments. The company operates at mid-cap biotech scale with a Boston headquarters and active R&D engine.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
4+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Adicet Bio?
AI assessmentHigh-risk, high-reward early-stage biotech requiring belief in science but demanding clarity on Series C timeline before joining.
Why Work Here
- Focused oncology pipeline with $99M R&D spend (FY2025) signals sustained commitment to immunotherapy development despite pre-revenue stage.
- Public company status (NASDAQ: ACET) provides equity liquidity and institutional credibility absent in private biotech.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Adicet Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.